These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24211008)

  • 1. Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.
    Yu P; Sun J; Wolz R; Stephenson D; Brewer J; Fox NC; Cole PE; Jack CR; Hill DL; Schwarz AJ;
    Neurobiol Aging; 2014 Apr; 35(4):808-18. PubMed ID: 24211008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
    Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
    J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
    Grill JD; Di L; Lu PH; Lee C; Ringman J; Apostolova LG; Chow N; Kohannim O; Cummings JL; Thompson PM; Elashoff D;
    Neurobiol Aging; 2013 Jan; 34(1):62-72. PubMed ID: 22503160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
    van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
    Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
    Lorenzi M; Donohue M; Paternicò D; Scarpazza C; Ostrowitzki S; Blin O; Irving E; Frisoni GB;
    Neurobiol Aging; 2010 Aug; 31(8):1443-51, 1451.e1. PubMed ID: 20541287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease.
    Cavedo E; Suppa P; Lange C; Opfer R; Lista S; Galluzzi S; Schwarz AJ; Spies L; Buchert R; Hampel H; ;
    J Alzheimers Dis; 2017; 60(1):151-164. PubMed ID: 28777748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.
    Joachim LK; Frölich L; Rüther E; Wiltfang J; Maier W; Kornhuber J; Bauer C; Heuser I; Peters O
    J Prev Alzheimers Dis; 2018; 5(3):202-206. PubMed ID: 29972214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the time to clinically worsening in mild cognitive impairment patients and its utility in clinical trial design by modeling a longitudinal clinical dementia rating sum of boxes from the ADNI database.
    Ito K; Hutmacher MM
    J Alzheimers Dis; 2014; 40(4):967-79. PubMed ID: 24531162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates.
    Duara R; Loewenstein DA; Greig MT; Potter E; Barker W; Raj A; Schinka J; Borenstein A; Schoenberg M; Wu Y; Banko J; Potter H
    Am J Geriatr Psychiatry; 2011 Nov; 19(11):951-60. PubMed ID: 21422909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal volume change measurement: quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST.
    Mulder ER; de Jong RA; Knol DL; van Schijndel RA; Cover KS; Visser PJ; Barkhof F; Vrenken H;
    Neuroimage; 2014 May; 92():169-81. PubMed ID: 24521851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort.
    Suppa P; Hampel H; Spies L; Fiebach JB; Dubois B; Buchert R;
    J Alzheimers Dis; 2015; 46(1):199-209. PubMed ID: 25720402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Your algorithm might think the hippocampus grows in Alzheimer's disease: Caveats of longitudinal automated hippocampal volumetry.
    Sankar T; Park MTM; Jawa T; Patel R; Bhagwat N; Voineskos AN; Lozano AM; Chakravarty MM;
    Hum Brain Mapp; 2017 Jun; 38(6):2875-2896. PubMed ID: 28295799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
    Kim GW; Kim BC; Park KS; Jeong GW
    Sci Rep; 2020 Jul; 10(1):10912. PubMed ID: 32616841
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.